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Prescription Monitoring Program 
Update
As of December 31, 2013, 4,496 prescribers have reg-
istered to use the prescription monitoring program (an 
increase of 19% from one year ago) and 2,081 pharma-
cists have registered to use the program (an increase of 
23% from one year ago). Between January 1, 2013 and 
December 31, 2013, a total of 178,226 requests for data 
were submitted to the program (an increase of 52% from 
one year ago). The program has registered 423 practitioner 
agents. The program is continuing to reduce the incidence 
of patients who utilize multiple pharmacies and multiple 
prescribers to obtain controlled substances (CS) in Iowa. 
The number of patients filling prescriptions for Schedule 
II, III, and IV CS and utilizing five or more prescribers or 
pharmacists has fallen from 3,293 in 2009, to 371 in 2013 
(a decrease of 89%). In the past five years, the number 
of doses of CS dispensed to patients in Iowa has grown 
14%, from 228,149,732 doses in 2009, to 260,092,453 
doses in 2013.
Joint Position Statement on 
Telepharmacy in Iowa
Iowa pharmacy stakeholders, including the Iowa 
Pharmacy Association, the Iowa Board of Pharmacy, 
the University of Iowa College of Pharmacy, and Drake 
University College of Pharmacy and Health Sciences, 
released the following position statement on telepharmacy 
on January 16, 2014.
1. The Iowa Pharmacy Association has adopted poli-
cies on telepharmacy practice and the Board has 
adopted administrative rules that currently allow 
telepharmacy in both hospital and community prac-
tice settings.
2. The Board has granted waivers of current telephar-
macy rules to sites that provide medications with-
out the use of automated medication distribution 
systems. 
3. The Board has granted pilot projects to additional 
sites to further explore and study other applications 
of telepharmacy.
4. The waivers and pilot projects will continue under 
the purview of the Board, and data from these sites 
performing telepharmacy services will be collected 
and analyzed.
5. The waivers and pilot projects are providing valuable 
information on medication access and patient safety 
in alternative drug delivery models.
6. The waivers and pilot projects will proceed over the 
next few years and allow the profession to develop 
“best practices” for telepharmacy.
7. The Iowa Pharmacy Association and the Board 
have established an ongoing task force to develop 
standards for the practice of telepharmacy in Iowa.
8. The telepharmacy task force will review the results 
of the waivers and pilot projects and will develop 
guiding principles to direct future rulemaking and 
legislative efforts.
9. The practice of telepharmacy presents both oppor-
tunities and risks for patients in Iowa. A thoughtful 
and deliberative process is needed to maximize 
patient safety and to allow appropriate medication 
access in all practice settings while maintaining the 
integral role of the pharmacist in the health care 
delivery system. 
Joint Task Force on Telepharmacy
The Iowa Pharmacy Association and the Board have 
formed a new task force on telepharmacy that will be 
meeting throughout calendar year 2014. The members of 
the task force are Brett Barker, NuCara Pharmacy; Mike 
Brownlee, University of Iowa Hospitals and Clinics; 
Renae Chesnut, Drake University College of Pharmacy and 
Health Sciences; Michele Evink, Clarke County Hospital; 
Ryan Frerichs, Meyer Pharmacy; Susan Frey, Hy-Vee, Inc 
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scription fee for pharmacies that service LTC facilities and oth-
ers. Please visit ISMP’s Web site at www.ismp.org/Newsletters/
longtermcare for more information, and let your LTC facilities 
know about this free offer.  
Here are a few excerpts from a recent issue.
Immediate Vs Extended Release Error
A physician called a LTC facility to change a resident’s 
oxycodone order from an extended-release formulation 
to an immediate release formulation at the same dose and 
frequency. The nurse receiving the verbal order transcribed it as 
“Discontinue OxyContin 10 mg BID, Start OxyContin 10 mg IR 
BID,” with “IR” meant to represent immediate release. Although 
OxyContin® is a brand of oxycodone, it is only available as 
an extended-release tablet. The pharmacy had previously been 
dispensing OxyContin for the resident, so the nurse thought she 
could communicate the prescriber’s order by discontinuing the 
current OxyContin order and then ordering OxyContin as an 
immediate-release product. The pharmacy continued dispensing 
OxyContin. The differences between these products and 
formulations were brought to the attention of nursing staff via 
an in-service. To minimize the risk of confusion, do not attach 
modifiers such as “IR” for immediate-release or “RS” for regular 
strength unless it is part of the official drug name.
Errors Occur During Transitions of Care
A pharmacist reported the following hazardous situation that 
can occur during a hospital to LTC transfer. Residents are often 
admitted to a LTC facility with a list of medications printed from 
the hospital pharmacy computer. On these printouts, doses are 
expressed along with the number of tablets. For example, the 
printout may list hydrochlorothiazide 50 mg/2 tablets daily for 
an order in which the total dose was 50 mg because the hospital 
only stocks the 25 mg tablets. During hospitalization the patient 
required two tablets for each dose; however, the LTC nurse may 
misinterpret the order to mean two 50 mg tablets, making the 
total dose 100 mg, or two times more than prescribed. This issue 
arises every time the resident’s total dose in the hospital requires 
more than one tablet or capsule. Discharge medication summaries 
and transfer orders should only list the total dose in mg or mcg 
and other directions for use (ie, frequency, route, drug name) to 
avoid misinterpretation.
2013 USP Chapter <797> Compliance 
Survey Shows Compliance Trends 
Unchanged From 2012 
The 2013 United States Pharmacopoeia (USP) Chapter 
<797> Compliance Survey, the third annual report released since 
2011, shows that the overall compliance rate of 77.2% remains 
nearly unchanged from the 2012 rate. Budgetary restrictions 
and physical plant limitations were among the top challenges to 
compliance by survey respondents. The report also details the 
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Changes to Fentanyl Pain Patch Warnings 
Required by FDA
To reduce the risk of accidental exposure, Food and Drug 
Administration (FDA) has announced new requirements that 
change the appearance of fentanyl pain patch warnings to make 
them more visible. The change also requires new language in the 
warning that emphasizes the risk of death from accidental expo-
sure, particularly in children. The announcement coincided with a 
Consumer Update that stressed the potential danger of improperly 
discarded fentanyl patches to children and pets. FDA reminded 
consumers of the agency’s previous advice for securely storing 
unused patches and disposing of used fentanyl patches by folding 
the sticky sides together and then flushing them down the toilet. 
The agency also advises patients to cover in-use patches with an 
adhesive film to keep them from coming loose, and to regularly 
check patches to ensure they are securely in place. FDA offers 
additional information for health care providers on the “Fentanyl 
Transdermal System (marketed as Duragesic) Information” page, 
available at www.fda.gov/Drugs/DrugSafety/PostmarketDrug 
SafetyInformationforPatientsandProviders/ucm114961.htm. 
Consumer information about safe drug disposal methods is also 
available on the AWARXE® Web site at www.AWARErx.org.
New: Free ISMP Medication Safety Alert! 
Newsletter for LTC Facilities 
This column was prepared by the Institute 
for Safe Medication Practices (ISMP). 
ISMP is an independent nonprofit agency 
and federally certified patient safety organization that analyzes 
medication errors, near misses, and potentially hazardous 
conditions as reported by pharmacists and other practitioners. 
ISMP then makes appropriate contacts with companies and 
regulators, gathers expert opinion about prevention measures, 
and publishes its recommendations. To read about the risk 
reduction strategies that you can put into practice today, 
subscribe to ISMP Medication Safety Alert!® Community/
Ambulatory Care Edition by visiting www.ismp.org. ISMP is a 
federally certified patient safety organization, providing legal 
protection and confidentiality for submitted patient safety data 
and error reports. ISMP is also an FDA MedWatch partner. Call 
1-800/FAIL-SAF(E) to report medication errors to the ISMP 
Medication Errors Reporting Program or report online at www 
.ismp.org. ISMP address: 200 Lakeside Dr, Suite 200, Horsham, 
PA 19044. Phone: 215/947-7797. E-mail: ismpinfo@ismp.org.
In July, ISMP began publishing Long-Term Care Advise-ERR, 
a new ISMP Medication Safety Alert! newsletter for nurses and 
administrators in long-term care (LTC) facilities. ISMP receives 
error reports that have occurred in LTC facilities. The newsletter 
is provided free to LTC facilities in the United States thanks in 
part to corporate sponsorship from Lilly and for a nominal sub-
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survey’s findings on what types of facilities are participating in 
compounding, and compliance in specific domain areas such as 
environmental sampling and gloved fingertip sampling. Of the 
survey’s 1,045 participants, 97% of the survey’s respondents 
said that USP Chapter <797> “has had a positive influence on 
patient safety.” The report notes National Association of Boards 
of Pharmacy® (NABP®) efforts to assist state boards of pharmacy 
in evaluating pharmacy compliance with USP Chapter <797> 
requirements for sterile compounding in their states. The report 
also noted that those who participated in the 2011 survey had a 
higher compliance score than those who did not. The survey’s 
authors encouraged pharmacy owners with multiple areas of 
noncompliance to target one or two areas to improve. They 
also encouraged organizations that participated in the survey to 
make use of the free Action Plan – generated upon completion 
of the survey – and other free resources to “reshape” their sterile 
compounding practices. The full report on the survey’s results 
is available in the October 2013 issue of Pharmacy Purchasing 
& Products Magazine and on the magazine’s Web site at www 
.pppmag.com/article/1403. 
FDA Recommends Schedule II 
Classification for Hydrocodone 
Combination Products
FDA planned to submit a formal recommendation to reclassify 
hydrocodone combination products as Schedule II controlled 
substances to the Department of Health and Human Services 
by early December 2013. FDA expects the National Institute 
on Drug Abuse to concur with the recommendation, indicates a 
statement on the FDA Web site. FDA also indicates that while 
“the value of and access to these drugs has been a consistent 
source of public debate,” the agency has “been challenged with 
determining how to balance the need to ensure continued access 
to those patients who rely on continuous pain relief while ad-
dressing the ongoing concerns about abuse and misuse.” Drug 
Enforcement Administration makes the final decision about the 
appropriate scheduling of these drugs. In January 2013, FDA’s 
Drug Safety and Risk Management Advisory Committee made 
a recommendation that hydrocodone combination products be 
classified as Schedule II drugs following a 19-to-10 vote that 
concluded a two-day meeting during which members discussed 
the potential for abuse and misuse of the medications and the 
potential impact of rescheduling the drug products. FDA’s state-
ment on the recommendation is available at www.fda.gov/Drugs/
DrugSafety/ucm372089.htm. 
New FDA Drug Info Rounds Training 
Videos Available 
FDA Drug Info Rounds, a series of online videos, provides 
important and timely drug information to practicing clinical and 
community pharmacists so they can help patients make better 
medication decisions. In the latest two Drug Info Rounds vid-
eos, pharmacists discuss the review and approval of new drug 
names and the review of marketing and advertising materials for 
new drugs. The videos can be viewed at www.fda.gov/Drugs/
ResourcesForYou/HealthProfessionals/ucm368620.htm and 
www.fda.gov/Drugs/ResourcesForYou/HealthProfessionals/
ucm371785.htm, respectively. Drug Info Rounds is developed 
with contributions from pharmacists in FDA’s Center for Drug 
Evaluation and Research, Office of Communications, and Divi-
sion of Drug Information.
CPPA Developing Specialty Pharmacy 
Accreditation Program
The Center for Pharmacy Practice Accreditation® (CPPA) has 
announced the development of a new accreditation program for 
specialty pharmacy practices. CPPA Executive Director Lynnae 
Mahaney, MBA, RPh, FASHP, VHA-CM, indicates that “CPPA 
will be able to develop the new specialty pharmacy standards 
quickly and efficiently with the existing standards development 
methodology, infrastructure, and network of specialty pharmacy 
expertise.”
CPPA is a partnership between the American Pharmacists As-
sociation, the American Society of Health-System Pharmacists, 
and NABP. CPPA develops and implements comprehensive 
programs of pharmacy practice site accreditation, including the 
promotion, development, and maintenance of principles, poli-
cies, and standards. CPPA offers the general public and users of 
pharmacy services a means of identifying those pharmacies that 
satisfy the accreditation criteria and are focused on advancing 
patient care, safety, and quality.
More information may be found in the press release, available 
at www.pharmacypracticeaccredit.org/news/2013/10/cppa-to-
develop-specialty-pharmacy-accreditation-program.
Pharmacists & Technicians: 
Don't Miss Out on Valuable CPE Credit. 
Set Up Your NABP e-Profile and  
Register for CPE Monitor Today!
Continuing pharmacy education (CPE) providers who are accredited 
by the Accreditation Council for Pharmacy Education (ACPE) have 
integrated CPE Monitor® into their systems and are requiring pharmacists 
and pharmacy technicians to provide a National Association of Boards 
of Pharmacy® (NABP®) e-Profile ID number and date of birth (MMDD) 
in order to process ACPE-accredited CPE credit.
Visit www.MyCPEmonitor.net to set up your NABP e-Profile and 
register for CPE Monitor and avoid possible delays in your CPE reporting.
CPE Monitor is a national collaborative service from  
NABP, ACPE, and ACPE providers that will allow licensees  
to track their completed CPE credit electronically.
National Association of Boards of Pharmacy Foundation, Inc
1600 Feehanville Drive
Mount Prospect, IL 60056
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(member, Board of Pharmacy); Felix Gallagher, PharmServ 
Solutions; Randy McDonough, Towncrest Pharmacy; 
Jim Miller, Mercy Family Pharmacy (member, Board of 
Pharmacy); John Swegle, Mercy Medical Center; Judy 
Trumpy (public member, Board of Pharmacy); and Sam 
Zoske, Medicap/Beans Pharmacy.
50-Year Pharmacists
The Board congratulates the following 18 Iowa phar-
macists who were originally licensed in 1964, have con-
tinuously maintained their Iowa pharmacist license, and 
have devoted a half-century of service to the public and 
the profession:
 ♦ Donald L. Avise, West Des Moines, IA
 ♦ Jean C. Abrahamson, Edmond, OK
 ♦ John T. Capper, Parnell, IA
 ♦ Bernard J. Cremers, Iowa City, IA
 ♦ Dennis D. Dobesh, Newton, IA (retired Board 
compliance officer)
 ♦ Harvey J. Eernisse, Fort Dodge, IA
 ♦ Louis P. Gaffney, Sioux Falls, SD
 ♦ Jack A. Gile, North Ft Myers, FL
 ♦ Alan J. Henricks, Dubuque, IA
 ♦ Russell C. Imboden, Huntersville, NC
 ♦ Gary L. Jones, Ottumwa, IA
 ♦ Dennis D. Killion, Red Oak, IA
 ♦ Thomas C. Lehman, Carroll, IA
 ♦ Paul J. Miller, Chico, CA
 ♦ Charles E. Nigut, Des Moines, IA
 ♦ William H. Reimer, Elkader, IA
 ♦ Jerome Schweitzer, Bedford, IA
 ♦ John A. Susich, Las Vegas, NV
Next Board Meeting
The Board plans to hold its next meeting on March 11-
12, 2014. Administrative hearings and a closed session 
will be held at the Board office in Des Moines on March 
11. The Board plans to meet in open session on March 
12. Please contact the Board office at 515/281-5944 to 
confirm times and locations.
Board Website
Please visit the Board’s website at www.state.ia.us/
ibpe/. 
Board Mission
The Iowa Board of Pharmacy promotes, preserves, and 
protects the public health, safety, and welfare through the 
effective regulation of the practice of pharmacy and the 
licensing of pharmacies, pharmacists, and others engaged 
in the sale, delivery, or distribution of prescription drugs 
and devices. Iowa Code §155A.2(1).
Follow the Board on Facebook and 
Twitter
Continued from page 1
Facebook “Iowa Board of Pharmacy”
www.facebook.com/pages/Iowa-Board-of-
Pharmacy/223126781053672
Twitter “IABoardPharmacy”
http://twitter.com/#!/IABoardPharmacy
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Iowa Medicine TLC is sponsored by the Governor’s Office of Drug Control Policy and administered by the 
Iowa Substance Abuse Information Center, a program funded by the Iowa Department of Public Health 
February 2014 
 
 
Dear Iowa Health Care Professional: 
 
The Iowa Medicine TLC project, in partnership with the Iowa Substance Abuse Information 
Center, Governor’s Office of Drug Control Policy, and the Iowa Prescription Abuse Reduction 
Task Force, requests your assistance to prevent the misuse of prescription medicines. 
 
Due in large part to you and other conscientious health care professionals, Iowa has the 
nation’s lowest rate of past year prescription pain reliever abuse. However, we also know 
prescription drug abuse is the fastest growing form of substance abuse in our state, threatening 
the well-being of an increasing number of Iowans. Iowa Medicine TLC wants to help you 
continue to educate and empower Iowans to avoid this dangerous behavior. 
 
The “TLC” in our name stands for Talk, Lock, and Connect. We developed an info-card to 
help Iowans understand how they can practice TLC to prevent medicine misuse at home. Feel 
free to refer patients to IowaMedicineTLC.org for this and other important information. 
 
For a free supply of Iowa Medicine TLC cards that you can give to patients, please contact the 
Iowa Substance Abuse Information Center toll-free at 866/242-4111. 
 
Finally, we hope you find Iowa’s Prescription Monitoring Program (PMP) helpful in coordinating 
patient use of controlled prescription drugs, to enhance patient care and prevent the diversion or 
misuse of medications. For more information, go to the Iowa Pharmacy Board’s PMP website at 
http://www.state.ia.us/ibpe/pmp/pmp-info.html or call 515/281-5944. 
 
Thanks in advance for your participation in Iowa Medicine TLC, and for your ongoing efforts to 
promote the health and safety of Iowans! 
 
Sincerely, 
 
Emily J. Blomme     Steven F. Lukan 
Iowa Medicine TLC     Governor’s Office of Drug Control Policy 
